Sacubitril/valsartan protects against arsenic trioxide induced cardiotoxicity in vivo and in vitro

Wu, Zhiqiang; Chen, Hongzhu; Lin, Liwang; Lü, Jing; Zhao, Qilei; Dong, Zengxiang; Hai, Xin

doi:10.1093/toxres/tfac018

Cited by 8 publications

(3 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It might be secondary to increased oxidative stress and intracellular calcium overload. Several ongoing studies are investigating the potential of antioxidant and anti-inflammatory agents such as sacubitril/valsartan, resveratrol, L-ascorbic acid, and omega-3 fatty acids as potential therapeutic options to attenuate arsenic-induced cardiotoxicity [ 25 , 27 , 28 , 29 ]. Further research is needed to fully investigate and validate the efficacy of these treatments.…”

Section: Qt Prolongationmentioning

confidence: 99%

Acute Promyelocytic Leukemia: Review of Complications Related to All-Trans Retinoic Acid and Arsenic Trioxide Therapy

Ghiaur,

Doran,

Gaman

et al. 2024

Cancers

View full text Add to dashboard Cite

The hallmark of acute promyelocytic leukemia (APL) is the presence of the characteristic fusion transcript of the promyelocytic leukemia gene with the retinoic acid receptor α gene (PML::RARA). The PML::RARA fusion is a molecular target for all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Therapies based on ATRA plus ATO have excellent outcomes in terms of complete remission rates, overall survival, and achievement of deep and durable molecular responses with a very low incidence of relapse. However, although the combination of ATRA and ATO has lower hematologic toxicity than standard chemotherapy, its use is associated with a spectrum of distinctive toxicities, such as differentiation syndrome, liver toxicity, QT interval prolongation, and neurotoxicity. Rigorous monitoring of patients’ clinical evolution is indispensable for identifying and addressing each complication. The objective is to maintain an equilibrium between treatment-induced adverse events and therapeutic efficacy. This paper focused on non-hematologic complications associated with the combination of ATRA and ATO. Additionally, we discuss late-onset complications of this therapy. In summary, the majority of treatment-related adverse events are manageable, self-limiting, and reversible. More so, there seems to be a lower incidence rate of secondary neoplasms compared to standard chemotherapy. However, further research is required to assess how the ATRA plus ATO regimen affects the emergence of additional comorbidities.

show abstract

Section: Qt Prolongationmentioning

confidence: 99%

Acute Promyelocytic Leukemia: Review of Complications Related to All-Trans Retinoic Acid and Arsenic Trioxide Therapy

Ghiaur,

Doran,

Gaman

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…Protease inhibitor [37][38][39] Bortezomil/carfezomil CHF/myocardial ischemia/hypertension 1.8-7.2 Endocrinotherapy [40] Goserin/levoprorelin/flutamide/bicalutamide Myocardial infarction/CHF 0.1-5 CART cell therapy [41,42] Tisagenlecleucel/axicabtagene ciloleucel Tachycardia/hypotension/cardiac insufficiency Unclear Arsenic trioxide [43,44] Arsenic trioxide/all-trans retinoic acid Prolonged QT interval/tachycardia 16 Hematopoietic stem cell transplantation [45] Lenalidomide, bortezomib, Isazzomib Arrhythmia/myocardial ischemia/CHF 2-12…”

Section: -34mentioning

confidence: 99%

“…Patients who began taking sacubitril/valsartan in hospital had a lower risk profile for heart failure rehospitalization and cardiovascular death than patients with a delayed initiation of sacubitril/valsartan (8 weeks later) [39] . The clinical trials of sacubitril/valsartan in HFrEF were shown in Table 2 [37][38][39][40][41][42][43][44][45][46][47][48] . LV remodeling was crucial in progression to HFrEF [70] .…”

Section: Sacubitril/valsartan In Heart Failure Reduced Ejection Fractionmentioning

confidence: 99%

Cancer treatment-related cardiotoxicity: a focus on sacubitril/valsartan

Feng

Chen

et al. 2023

Cardiology Plus

View full text Add to dashboard Cite

Cardiotoxicity is the most dramatic complication of cancer therapies, and it results in the cessation of potentially life-saving antitumor treatment regimens and a poor survival prognosis in a nonnegligible proportion of patients. Angiotensin converting enzyme inhibitors (ACEIs) and β-blockers are effective in the treatment of cancer therapy-related cardiac dysfunction (CTRCD), whereas their roles in the prevention of cardiotoxicity are unclear. Sacubitril/valsartan, which is an angiotensin receptor-neprilysin inhibitor, has been shown to be advantageous over ACEIs in heart failure patients with reduced ejection fraction for further the reduction of cardiovascular death or rehospitalization. However, patients with CTRCD were excluded from pivotal trials involving sacubitril/valsartan. Although several small observational studies have observed excellent performance in improving cardiac structure and function in patients with CTRCD, large-scale prospective clinical studies are required to confirm these results. In this review, we described the contemporary literature concerning the potential benefit of sacubitril/valsartan in the cardio-oncology setting.

show abstract

Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats

Nordén,

Bendiksen,

Bergo

et al. 2024

ESC Heart Failure

View full text Add to dashboard Cite

AimsSacubitril/valsartan (Sac/Val) is used for treatment of heart failure. The effect of Sac/Val on regional dysfunction following myocardial infarction (MI) remains uncertain. This study aimed at understanding the effects of Sac/Val on regional function after MI.Methods and resultsMI or sham surgery was performed in Sprague–Dawley rats. Animals were randomized to treatment with Sac/Val, valsartan (Val) or vehicle (Veh). Magnetic resonance imaging was used to acquire left ventricular volumes and strain. Left ventricular tissue was obtained for wesern blotting, PCR and Masson's trichrome staining. Isolated cardiac fibroblasts were cultured with Veh, atrial natriuretic peptide (ANP), adrenomedullin (ADM) and sacubitrilat, and collagen expression assessed with droplet digital PCR.ResultsSac/Val reduced ventricular end‐diastolic volume by 18% compared with Veh, and preserved circumferential systolic strain in the zone proximal to infarction compared with sham after 42 days of treatment (peak strain ± SEM: sham: −0.19 ± 0.01%; Sac/Val: −0.14 ± 0.02%; Val: −0.10 ± 0.02%; Veh: −0.10 ± 0.02%). Masson's trichrome staining demonstrated lower fibrotic deposition in the intermediate zone with Sac/Val treatment than Veh (sham: 2.29 ± 0.17%; Sac/Val: 2.31 ± 0.27%; Val: 3.22 ± 0.60%; Veh: 4.14 ± 0.48%). The amounts of the pro‐apoptotic caspase 3 cleavage fragments p19/17 were 89% higher in Val than sham, with Sac/Val showing no significant increase compared with sham. Collagen expression in human fibroblast culture was lower in cells co‐treated with sacubitrilat and ANP, an effect not observed with sacubitrilat/ADM co‐treatment.ConclusionsSac/Val preserves in vivo myocardial function in the region most proximal to MI in rats and reduces left ventricular dilatation. These effects may be related to a reduction in both fibrosis and pro‐apoptotic signalling.

show abstract

Sacubitril/valsartan protects against arsenic trioxide induced cardiotoxicity in vivo and in vitro

Cited by 8 publications

References 37 publications

Acute Promyelocytic Leukemia: Review of Complications Related to All-Trans Retinoic Acid and Arsenic Trioxide Therapy

Acute Promyelocytic Leukemia: Review of Complications Related to All-Trans Retinoic Acid and Arsenic Trioxide Therapy

Cancer treatment-related cardiotoxicity: a focus on sacubitril/valsartan

Sacubitril/valsartan preserves regional cardiac function following myocardial infarction in rats

Contact Info

Product

Resources

About